Immunotherapy's hidden danger: study probes blood vessel damage
NCT ID NCT07535944
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 200 cancer patients starting immune checkpoint inhibitors (ICIs) to see if these drugs stiffen the arteries. Researchers will measure pulse wave velocity before treatment, after 6-8 weeks, and at one year. The goal is to better understand vascular side effects like vasculitis and blood clots, which may become more common as ICI use grows.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Immune checkpoint inhibitors (ICIs) such as nivolumab, pembrolizumab, atezolizumab, ipilimumab, cemiplimab, and others
- What this could lead to
- If successful, this study could help doctors understand and monitor blood vessel problems caused by immunotherapy, leading to better safety guidelines.
- What could go wrong
- This is an early observational study with no treatment being tested. It only measures changes in artery stiffness, so it may not capture all vascular risks or lead to direct patient benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULAR COMPLICATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de ROUEN
Rouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.